Rationally designed bacterial consortia to treat chronic immune-mediated colitis and restore intestinal homeostasis

Daniel van der Lelie; Akihiko Oka; Safiyh Taghavi; Junji Umeno; Ting-Jia Fan; Katherine E. Merrell; Sarah D. Watson; Lisa Ouellette; Bo Liu; Muyiwa Awoniyi; Yunjia Lai; Liang Chi; Kun Lu; Christopher S. Henry; R. Balfour Sartor

doi:10.1038/s41467-021-23460-x

Nature Communications (May 2021)

Rationally designed bacterial consortia to treat chronic immune-mediated colitis and restore intestinal homeostasis

Daniel van der Lelie,
Akihiko Oka,
Safiyh Taghavi,
Junji Umeno,
Ting-Jia Fan,
Katherine E. Merrell,
Sarah D. Watson,
Lisa Ouellette,
Bo Liu,
Muyiwa Awoniyi,
Yunjia Lai,
Liang Chi,
Kun Lu,
Christopher S. Henry,
R. Balfour Sartor

Affiliations

Daniel van der Lelie: Gusto Global LLC
Akihiko Oka: Departments of Medicine, Microbiology and Immunology, Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill
Safiyh Taghavi: Gusto Global LLC
Junji Umeno: Departments of Medicine, Microbiology and Immunology, Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill
Ting-Jia Fan: Gusto Global LLC
Katherine E. Merrell: Gusto Global LLC
Sarah D. Watson: Gusto Global LLC
Lisa Ouellette: Gusto Global LLC
Bo Liu: Departments of Medicine, Microbiology and Immunology, Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill
Muyiwa Awoniyi: Departments of Medicine, Microbiology and Immunology, Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill
Yunjia Lai: Department of Environmental Sciences and Engineering, Gillings School of Public Health, University of North Carolina at Chapel Hill
Liang Chi: Department of Environmental Sciences and Engineering, Gillings School of Public Health, University of North Carolina at Chapel Hill
Kun Lu: Department of Environmental Sciences and Engineering, Gillings School of Public Health, University of North Carolina at Chapel Hill
Christopher S. Henry: Gusto Global LLC
R. Balfour Sartor: Departments of Medicine, Microbiology and Immunology, Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill

DOI: https://doi.org/10.1038/s41467-021-23460-x
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 17

Abstract

Read online

Fecal microbiota transplantation and probiotics have been tested/used as potential therapeutics against inflammatory bowel diseases (IBD). Here the authors use a bottom-up rational consortium design approach that combines well-characterized strains isolated from healthy human stool samples to produce two consortia of metabolically interdependent strains for the treatment of IBD.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal